Content about J. Michael Pearson

January 31, 2014

Valeant Pharmaceuticals International announced that it received approval from the Food and Drug Administration for Retin-A Micro (tretinoin) gel microsphere 0.08%.

LAVAL, Quebec — Valeant Pharmaceuticals International, a specialty pharmaceutical company, on Friday announced that it received approval from the Food and Drug Administration for Retin-A Micro (tretinoin) gel microsphere 0.08%, which is used for the topical treatment of acne vulgaris.

December 16, 2013

Valeant Pharmaceuticals International will acquire Solta Medical for about $250 million, Valeant said Monday.

LAVAL, Quebec — Valeant Pharmaceuticals International will acquire Solta Medical for about $250 million, Valeant said Monday.

The Canadian drug maker said the $2.92-per-share acquisition represented a 40% premium over Solta's closing share price on Friday. Solta develops, manufactures and markets energy-based medical device systems for such cosmetic medical procedures as skin tightening, improving skin texture and others.

November 15, 2013

The Food and Drug Administration has approved a new drug for fungal infections of the skin made by Valeant Pharmaceuticals International, the drug maker said Friday.

LAVAL, Quebec — The Food and Drug Administration has approved a new drug for fungal infections of the skin made by Valeant Pharmaceuticals International, the drug maker said Friday.

The company announced the FDA approval of Luzu (luliconazole) cream in the 1% strength for treatment of athlete's foot, jock itch and ringworm in adults.

October 2, 2013

Drug maker Valeant Pharmaceuticals International is joining an effort to oppose domestic violence, the company said Wednesday.

LAVAL, Quebec — Drug maker Valeant Pharmaceuticals International is joining an effort to oppose domestic violence, the company said Wednesday.

Valeant announced that it had formed a partnership with the National Coalition Against Domestic Violence to help raise awareness of the problem, with plans to donate a portion of sales from Medicis and Obagi products to the organization.

September 18, 2012

Valeant Pharmaceuticals CFO Howard Schiller has been appointed to the drug maker's board of directors.

MONTREAL — Valeant Pharmaceuticals CFO Howard Schiller has been appointed to the drug maker's board of directors.

Schiller joined Valeant as EVP and CFO in December 2011, following a 24-year career at Goldman Sachs. Schiller also serves on the New York board of Teach for America and on the board of the Cancer Research Institute. In addition, he also is on the business advisory council of the University of Chicago Law School.

September 4, 2012

Canadian drug maker Valeant Pharmaceuticals International is buying Medicis Pharmaceutical for $2.6 billion, Valeant said Monday.

MONTREAL — Canadian drug maker Valeant Pharmaceuticals International is buying Medicis Pharmaceutical for $2.6 billion, Valeant said Monday.

The $44-per-share deal, which the companies said represents a 39% premium over the closing price of Medicis' shares on Friday, is expected to close in the first half of 2013.

March 22, 2011

J. Michael Pearson has been appointed to chairman of the board at Valeant Pharmaceuticals, the drug maker said Tuesday.

MISSISSAUGA, Ontario — J. Michael Pearson has been appointed to chairman of the board at Valeant Pharmaceuticals, the drug maker said Tuesday.

Pearson, who is Valeant's CEO, will extend his contract with Valeant through February 2017, the company said.

Pearson replaces current chairman Robert Ingram, who remains on the board as an independent board director and lead director.

October 31, 2010

Valeant Pharmaceuticals International's subsidiary Biovail Labs International has agreed to acquire several privately owned skin...